宫颈癌高剂量率近距离放疗高危临床靶区及危及器官分次间剂量变化的统计分析
回顾性分析50例2019年10月至2020年12月接受高剂量率腔内近距离放疗的宫颈癌患者,量化高危临床靶区(HRCTV)相对于处方剂量的分次间剂量变化(IDV)及其对危及器官(OAR)剂量的影响。HRCTV变化均值为-2.53%±8.74%,呈左偏分布,存在低估HRCTV剂量的倾向;HRCTV变化与OAR变化呈中至弱线性相关,其中膀胱D2cc相关性最强。
要点
- HRCTV相对于处方剂量的平均变化为-2.53%±8.74%,IDV呈左偏分布。
- HRCTV剂量低于处方5%的概率为30.0%(±2.62%,95%CI),高于处方5%的概率为23.3%(±2.62%,95%CI)。
- HRCTV变化与OAR变化呈中至弱线性相关,膀胱D2cc相关性最强。
核心结论
- HRCTV剂量变化与OAR变化复杂相关,其中膀胱D2cc相关性最强。
- HRCTV的IDV最佳描述为左偏分布,提示存在低估HRCTV剂量的倾向。
- 这种剂量变化的临床意义符合预期,并将进一步研究。
研究设计与样本
- 回顾性分析2019年10月至2020年12月接受高剂量率腔内近距离放疗的50例宫颈癌患者。
- 关注的危及器官为直肠、膀胱、乙状结肠和肠管。
- 评估剂量参数为90%的HRCTV吸收剂量(D90)及各OAR的D0.1cc和D2cc。
主要发现
- HRCTV相对于处方剂量的平均变化为-2.53%±8.74%。
- HRCTV变化与OAR变化呈中至弱线性相关,膀胱D2cc相关性最强。
- HRCTV剂量低于处方5%的概率为30.0%(±2.62%,95%CI),高于处方5%的概率为23.3%(±2.62%,95%CI)。
- 低估HRCTV剂量的倾向是HRCTV的IDV不呈正态分布的结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: High-dose-rate (HDR) brachytherapy for cervical cancer treatment includes significant uncertainties. The aim of this study was to quantify the interfraction dosimetric variation (IDV) of the high-risk clinical target volume (HRCTV) from the prescribed dose and the corresponding effect on organ-at-risk (OAR) dose based on a comprehensive statistical analysis. METHODS AND MATERIALS: Fifty patients with cervical cancer treated with high-dose-rate intracavity brachytherapy from October 2019 to December 2020 were retrospectively analyzed. The OARs of interest were the rectum, bladder, sigmoid, and bowel. The dosimetric parameters evaluated for all patients was the dose absorbed by 90% of the HRCTV ( D 90 ) and the dose absorbed by 0.1 ( D 0.1 c c ) and 2 cm3 ( D 2 c c ) of each respective OAR. The HRCTV variations were from the prescribed dose and the OAR variations were from the corresponding tolerance dose. Distribution fitting of the HRCTV variations was determined to quantify the IDV. Comparative statistics of the HRCTV variations with the OAR variations were conducted to determine correlations. RESULTS: The mean HRCTV variation from the prescribed dose was -2.53% ± 8.74%. The HRCTV variations and OAR variations showed moderate to weak linear correlations despite the variations being relative to each other, with the bladder D 2 c c having the strongest correlation. There was a 30.0% (±2.62%, 95% confidence interval) probability of underdosing the HRCTV (-5% variation from prescription) and a 23.3% (±2.62%, 95% confidence interval) probability of overdosing the HRCTV (+5% variation from prescription). This tendency to underdose the HRCTV was a consequence of HRCTV IDV not being normally distributed. CONCLUSIONS: HRCTV dosimetric variations and OAR variations were complexly correlated with the bladder D 2 c c having the strongest correlation. HRCTV IDV was best described as a left-skewed distribution that indicates a tendency of underdosing the HRCTV. The clinical significance of such dose variations is expected and will be further investigated.
引用
- Washington B, Randall M, Fabian D, et al. Statistical Analysis of Interfraction Dose Variations of High-Risk Clinical Target Volume and Organs at Risk for Cervical Cancer High-Dose-Rate Brachytherapy. Adv Radiat Oncol. 2022. PMID: 36110265. doi:10.1016/j.adro.2022.101019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。